Investors sold shares of G1 Therapeutics Inc (NASDAQ:GTHX) on strength during trading hours on Friday. $2.97 million flowed into the stock on the tick-up and $16.88 million flowed out of the stock on the tick-down, for a money net flow of $13.91 million out of the stock. Of all equities tracked, G1 Therapeutics had the 0th highest net out-flow for the day. G1 Therapeutics traded up $0.36 for the day and closed at $40.47
Several research analysts have issued reports on the stock. BidaskClub raised shares of G1 Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Needham & Company LLC boosted their price objective on shares of G1 Therapeutics to $42.00 and gave the company a “buy” rating in a report on Tuesday, March 13th. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of G1 Therapeutics in a report on Wednesday, March 7th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $39.00 price objective (up from $33.00) on shares of G1 Therapeutics in a report on Tuesday, March 6th. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.20.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). analysts expect that G1 Therapeutics Inc will post -2.47 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alps Advisors Inc. raised its holdings in shares of G1 Therapeutics by 13.1% during the fourth quarter. Alps Advisors Inc. now owns 31,409 shares of the company’s stock valued at $623,000 after purchasing an additional 3,643 shares during the last quarter. Teachers Advisors LLC increased its holdings in G1 Therapeutics by 44.6% during the fourth quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after buying an additional 4,260 shares during the last quarter. Chartwell Investment Partners LLC increased its holdings in G1 Therapeutics by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after buying an additional 4,388 shares during the last quarter. American International Group Inc. purchased a new stake in G1 Therapeutics during the third quarter valued at approximately $130,000. Finally, Bank of New York Mellon Corp increased its holdings in G1 Therapeutics by 28.4% during the fourth quarter. Bank of New York Mellon Corp now owns 29,341 shares of the company’s stock valued at $582,000 after buying an additional 6,483 shares during the last quarter. 42.78% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3298851/investors-sell-g1-therapeutics-gthx-on-strength-gthx.html.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.